1 citations
,
February 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Baricitinib effectively promotes long-term hair regrowth in alopecia areata patients.
August 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” Placebo effects in alopecia treatments are likely due to study design, not real improvement.
January 2025 in “Journal of Crohn s and Colitis” Tofacitinib is effective and safe for elderly patients with ulcerative colitis.
High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.
Biorregulatory therapy significantly improved the dog's health, reversing previous issues and eliminating the need for ongoing medication.
1 citations
,
December 2023 in “Journal of the European Academy of Dermatology and Venereology”
January 2005 in “Translational and Clinical Pharmacology” HDMHG0401-10 improves hair loss in men with androgenetic alopecia and has no major side effects.
January 2024 in “Acta dermato-venereologica”
3 citations
,
August 2023 in “Drug safety” Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.
1 citations
,
March 2024 in “Skin health and disease” Vibration assisted analgesia reduces pain during corticosteroid therapy for alopecia.